Champions Oncology director granted stock options

Champions Oncology director Robert Lawrence Brainin reported multiple stock option awards over several years.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Champions Oncology director Robert Lawrence Brainin reported multiple stock option awards over several years. The Form 4 shows options to purchase common stock granted on November 5, 2021, November 1, 2022, November 3, 2023, and November 12, 2024, at exercise prices of $10.10, $7.00, $5.51, and $4.64 per share, respectively.

Each grant vests over twelve months in four installments on specified quarterly dates. After the most recent November 12, 2024 award of 23,030 options, Brainin beneficially owned 74,163 stock options directly, all expiring ten years from their respective grant dates.

Insider Trade Summary

Grant/Award: 66,131 shares

Grant/Award 4 txns

Insider Brainin Robert Lawrence

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase Common Stock	23,030	$4.64	$107K
Grant/Award	Option to purchase Common Stock	19,070	$5.51	$105K
Grant/Award	Option to purchase Common Stock	14,130	$7.00	$99K
Grant/Award	Option to purchase Common Stock	9,901	$10.10	$100K

Holdings After Transaction: Option to purchase Common Stock — 175,292 contracts (Direct)

Footnotes (4)

F1. The options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2021, February 5, 2022, May 5, 2022 and August 5, 2022, respectively.
F2. The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2022, February 1, 2023, May 1, 2023 and August 1, 2023, respectively.
F3. The options vest and are exercisable over a twelve month period, with vesting to occur on November 3, 2023, February 3, 2024, May 3, 2024 and August 3, 2024, respectively.
F4. The options vest and are exercisable over a twelve month period, with vesting to occur on November 12, 2024, February 12, 2025, May 12, 2025 and August 12, 2025, respectively.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did the CSBR Form 4 report for Robert Lawrence Brainin?

The filing reports a series of stock option awards to director Robert Lawrence Brainin. Options to purchase common stock were granted in 2021, 2022, 2023, and 2024 at exercise prices between $4.64 and $10.10, each with ten-year terms and structured vesting schedules.

How many Champions Oncology (CSBR) options does Robert Brainin hold after the latest grant?

After the November 12, 2024 award, Robert Brainin beneficially owned 74,163 stock options. This total reflects cumulative option grants reported in the Form 4, including the most recent 23,030 options, all held directly and tied to underlying shares of Champions Oncology common stock.

What are the exercise prices of the options granted to the CSBR director?

The options were granted with exercise prices of $10.10, $7.00, $5.51, and $4.64 per share. Each grant corresponds to a different award date from 2021 through 2024 and represents the cost per share to acquire Champions Oncology common stock.

How do the stock options for CSBR’s Robert Brainin vest over time?

Each option grant vests over a twelve-month period in four equal installments. Vesting dates occur roughly every three months following the grant, with specific schedules listed for the 2021, 2022, 2023, and 2024 awards, allowing gradual exercisability rather than immediate full vesting.

What are the expiration dates of the Champions Oncology options reported in this Form 4?

Each option grant carries a ten-year expiration from its respective grant date. The awards granted in 2021, 2022, 2023, and 2024 expire on November 5, 2031, November 1, 2032, November 3, 2033, and November 12, 2034, respectively, if not exercised earlier.

Is Robert Lawrence Brainin a director or officer of Champions Oncology (CSBR)?

Robert Lawrence Brainin is reported as a director of Champions Oncology. The Form 4 indicates his relationship to the issuer is as a director, with no officer title and not as a ten percent owner, while reflecting his holdings through the reported stock option awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/30/2026 - 12:15 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brainin Robert Lawrence

(Last)

(First)

(Middle)

C/O CHAMPIONS ONCOLOGY, INC

ONE UNIVERSITY PLAZA, SUITE 307

(Street)

HACKENSACK

07601

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CHAMPIONS ONCOLOGY, INC. [ CSBR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option to purchase Common Stock	$10.1	11/05/2021		A		9,901		⁽¹⁾	11/05/2031	Common Stock	9,901	$10.1	17,933	D
Option to purchase Common Stock	$7	11/01/2022		A		14,130		⁽²⁾	11/01/2032	Common Stock	14,130	$7	32,063	D
Option to purchase Common Stock	$5.51	11/03/2023		A		19,070		⁽³⁾	11/03/2033	Common Stock	19,070	$5.51	51,133	D
Option to purchase Common Stock	$4.64	11/12/2024		A		23,030		⁽⁴⁾	11/12/2034	Common Stock	23,030	$4.64	74,163	D

Explanation of Responses:

1. The options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2021, February 5, 2022, May 5, 2022 and August 5, 2022, respectively.

2. The options vest and are exercisable over a twelve month period, with vesting to occur on November 1, 2022, February 1, 2023, May 1, 2023 and August 1, 2023, respectively.

3. The options vest and are exercisable over a twelve month period, with vesting to occur on November 3, 2023, February 3, 2024, May 3, 2024 and August 3, 2024, respectively.

4. The options vest and are exercisable over a twelve month period, with vesting to occur on November 12, 2024, February 12, 2025, May 12, 2025 and August 12, 2025, respectively.

Remarks:

	/s/ Robert L. Brainin	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR